Department of Error (DOI:10.1016/S0140-6736(08)60485-7);Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

The Lancet

Volumn 371, Issue 9618, 2008, Pages 1073-1084

  Bretzel, Reinhard G ^a   Nuber, Ulrike ^a   Landgraf, Wolfgang ^b   Owens, David R ^c   Bradley, Clare ^d   Linn, Thomas ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c LLANDOUGH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; CORTICOSTEROID; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EUROPE; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORNING DOSAGE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT SATISFACTION; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 40949111213     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61305-7     Document Type: Erratum

References (48)

1. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
2. United Kingdom Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
3. Stratton I., Adler A., Neil H., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
4. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 suppl 1 (2006) S4-S42
5. International Diabetes Federation. Global guideline for type 2 diabetes (2005), International Diabetes Federation, Brussels
6. Nathan D., Buse J., Davidson M., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49 (2006) 1711-1721
7. United Kingdom Prospective Diabetes Study. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310 (1995) 83-88
8. Turner R., Cull C., Frighi V., and Holmann R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281 (1999) 2005-2012
9. Cryer P. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 45 (2002) 937-948
10. Cefalu W. Evaluation of alternative strategies for optimizing glycemia: progress to date. Am J Med 113 suppl 6A (2002) 23S-35S
11. Polonsky W., Fisher L., Guzman S., Villa-Caballero L., and Edelman S. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 28 (2005) 2543-2545
12. McCrimmon R., and Frier B. Hypoglycaemia, the most feared complication of insulin therapy. Diabete Metab 20 (1994) 503-512
13. Davidson J. Treatment of the patient with diabetes: importance of maintaining target HbA(1c) levels. Curr Med Res Opin 20 (2004) 1919-1927
14. Lepore M., Pampanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
15. Scholtz H., Pretorius S., Wessels D., and Becker R. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48 (2005) 1988-1995
16. Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedlak M., and Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23 (2000) 644-649
17. Porcellati F., Rossetti P., Busciantella N., et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 30 (2007) 2447-2452
18. Riddle M., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
19. Yki-Järvinen H., Dressler A., and Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23 (2000) 1130-1136
20. Janka H., Plewe G., Riddle M., Kliebe-Frisch C., Schweitzer M., and Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
21. Rosenstock J., Schwartz S., Clark Jr. C., Park G., Donley D., and Edwards M. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
22. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49 (2006) 442-451
23. Bastyr III E., Stuart C., Brodows R., et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 23 (2000) 1236-1241
24. DeWitt D., and Hirsch I. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 289 (2003) 2254-2264
25. Davis R., Lowes L., Cradock S., Dromgoole P., Mcdowell J., and On behalf of the United Kingdom Insulin Initiation Study Group. Insulin initiation among adults and children with diabetes in the United Kingdom. Practical Diabetes International 23 (2006) 171-174
26. McCance D., Ritchie C., and Kennedy L. Is HbA1 measurement superfluous in NIDDM?. Diabetes Care 11 (1988) 512-514
27. Landstedt-Hallin L., Adamson U., Arner P., Bolinder J., and Lins P. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 18 (1995) 1183-1186
28. Graf R., Halter J., and Porte Jr. D. Glycosylated hemoglobin in normal subjects and subjects with maturity-onset diabetes. Evidence for a saturable system in man. Diabetes 27 (1978) 834-839
29. Bonora E., Calcaterra F., Lombardi S., et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 24 (2001) 2023-2029
30. Jovanovic L., Giammattei J., Acquistapace M., Bornstein K., Sommermann E., and Pettitt D. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size. Clin Ther 26 (2004) 1492-1497
31. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
32. Bradley C., and Lewis K. Measures of psychological well-being and treatment satisfaction developed from responses of people treated with tablet-treated diabetes. Diabet Med 7 (1990) 445-451
33. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Bradley C. (Ed). Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice (1994), Harwood Academic Publishers, Chur, Switzerland 111-132
34. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 16 (1999) 716-730
35. Riedel A., and Plauschinat C. Failure rates associated with metformin, sulfonylurea and thiazolidinedione therapy for type 2 diabetes. Diabetes 55 suppl 1 (2006) A132 (abstr 553-P).
36. United Kingdom Prospective Diabetes Study. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. UK Prospective Diabetes Study Group. Diabetes Care 21 (1998) 87-92
37. Surwit R., van Tilburg M., Parekh P., Lane J., and Feinglos M. Treatment regimen determines the relationship between depression and glycemic control. Diabetes Res Clin Pract 69 (2005) 78-80
38. Eliaschewitz F., Calvo C., Valbuena H., et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 37 (2006) 495-501
39. Mullins P., Sharplin P., Yki-Jarvinen H., Riddle M., and Haring H. Negative binomial meta-regression of combined HbA1c and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared NPH insulin in Type 1 and Type 2 diabetes. Clin Ther 29 (2007) 1607-1619
40. Rosenstock J., Dailey G., Massi-Benedetti M., Fritsche A., Lin Z., and Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28 (2005) 950-955
41. Yki-Järvinen H., Haring H., Zeger S., Arbet-Engels C., Nguyen H., and Riddle M. The relationship between HbA1c, fasting blood glucose (FBG) and hypoglycemia using insulin glargine versus NPH insulin: a meta-regression analysis in Type 2 diabetes. Diabetes 52 suppl 1 (2003) A149 (abstr 642).
42. Holman R., Thorne K., Farmer A., et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. N Engl J Med 357 (2007) 1716-1730
43. Heine R., Van Gaal L., Johns D., Mihm M., Widel M., and Brodows M. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 143 (2005) 559-569
44. Secnik Boye K., Matza L., Oglesby A., et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 4 (2006) 80
45. National Heart Lung and Blood Institute. ACCORD Blood Sugar Treatment Strategy Announcement (Feb 6, 2008). http://www.nhlbi.nih.gov/health/prof/heart/other/accord (accessed Feb 15, 2008).
46. Action to Control Cardiovascular Risk in Diabetes. http://www.accordtrial.org/web/public/documents/Protocol%20All%20Chapter s.pdf?CFID=156360&CFTOKEN=73292543 (accessed Feb 15, 2008).
47. Peyrot M., Rubin R., Lauritzen T., et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
48. Davies M., Storms F., Shutler S., Bianchi-Biscay M., and Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28 (2005) 1282-1288